Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + docetaxel + Endostar
- Development stage
- Phase 2
- Lead developer
- Johnson Matthey
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy consisting of carboplatin (a platinum-containing drug), docetaxel (a taxane agent), and Endostar (recombinant human endostatin). Carboplatin and docetaxel work as chemotherapeutic agents, while Endostar is a vascular endothelial growth factor inhibitor that specifically acts on microvascular endothelial cells to inhibit tumor angiogenesis. This combination aims to provide both cytotoxic effects against cancer cells and anti-angiogenic effects to cut off tumor blood supply.
02
Targets
DNANeuraminidaseMicrotubuleVEGFR2 (Vascular endothelial growth factor receptor 2)TUBB (Tubulin (alpha and beta subunits))VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on carboplatin + docetaxel + Endostar.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + docetaxel + Endostar.